Q-omics provides the consensus-scored KRT18P59 profile across patient tissues and cancer cell-line models. KRT18P59 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT18P59 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, KRT18P59 RNA expression shows 17,505 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where KRT18P59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18P59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18P59 survival associations across molecular data types. KRT18P59 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18P59 RNA expression–survival associations across cancer types. High KRT18P59 expression shows unfavorable associations in KIRC, BRCA, MESO and STAD, but favorable associations in UCS and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT18P59 RNA expression.
This table summarizes KRT18P59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KRT18P59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18P59 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in COAD, LUSC and HNSC. The THCA box plot shows higher KRT18P59 RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p < 0.001).
This table shows molecular features associated with KRT18P59 in patient tissues and cancer cell lines. In patient samples, KRT18P59 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
